Clinical Trials Logo

Orgasmic Disorder clinical trials

View clinical trials related to Orgasmic Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT04824820 Completed - Clinical trials for Urinary Incontinence

Improving Female Sexual Wellness

Start date: April 10, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effect of commercially available genital vibrator use on sexual health, female pelvic floor disorders, and overall quality of life among a diverse population of women.

NCT ID: NCT04566783 Completed - Clinical trials for Sexual Arousal Disorder

Identification of Etiopathological and Clinical Factors in Persistent Genital Arousal Disorder

iPGAD
Start date: June 1, 2020
Phase:
Study type: Observational

Investigation of (possible etiological) factors associated with PGAD symptomatology as well as description of comorbid disorders subjects with PGAD. Persistent genital arousal disorder (PGAD) is a presumably rare, although debilitating condition, which was first defined at the beginning of this century and has not yet found consideration by any of the international classification systems of diseases. PGAD is commonly characterized by persistent and unwanted sensations of genital arousal which are not related to subjective feelings of sexual desire or arousal. Affected patients which are predominantly women can suffer tremendously. The lack of basic research on the etiology of PGAD leads to insufficient therapeutical approaches.

NCT ID: NCT00248209 Completed - Orgasmic Disorder Clinical Trials

Female Orgasmic Disorder (FOD) and Wellbutrin XL

Start date: May 2004
Phase: Phase 2/Phase 3
Study type: Interventional

A recently completed multi-site double-blind placebo-controlled study found that bupropion (Wellbutrin XL) increased female orgasmic function in a group of pre-menopausal women with a diagnosis of hypoactive sexual desire disorder. The purpose of this study is to ascertain whether bupropion will improve orgasmic function in pre-menopausal women with a primary complaint of idiopathic orgasmic disorder who do not have hypoactive sexual desire disorder. This will be a multicenter, placebo-controlled, double blind study of women with a diagnosis of female orgasm disorder. During a baseline visit, psychiatric, medical, alcohol and drug, and sexual histories will be obtained. Patients who continue to meet screening inclusion/exclusion criteria at their baseline visit will be randomly assigned to either placebo or bupropion XL for 8 weeks. A flexible dosing paradigm will be used. Sexual desire and activity will be assessed by patient diaries, investigator interview of sexual functioning every two weeks, and by standardized questionnaire every four weeks. The primary endpoint will be the increase in orgasm completion as measured by the Changes in Sexual Functioning Questionnaire-F (CSFQ-F). Secondary endpoints will be changes in sexual arousal, sexual desire, and sexual pleasure as assessed by the CSFQ-F.